Podcasts
Listen to the latest hemonc news from international experts
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Sequencing therapies in multiple myeloma: navigating an expanding treatment landscape
This VJHemOnc podcast explores the evolving treatment landscape in multiple myeloma, focusing on treatment selection and sequencing across the disease course. Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses shared decision-making in frontline treatment, while Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, explores sequencing CAR T-cell therapies and bispecific antibodies, including the choice between BCMA- and GPRC5D-directed approaches. Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, reviews updated findings from the MajesTEC-3 trial (NCT05083169) of teclistamab plus daratumumab in high-risk disease, and Peter Voorhees discusses Phase III MonumenTAL-3 (NCT05455320) data evaluating talquetamab plus daratumumab, with or without pomalidomide. Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, highlights strategies for managing infections associated with bispecific antibodies, while Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the transition towards community-based delivery of bispecific therapies.
Date: 24th August 2026
